# A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer

> **NCT07294534** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 817 (estimated)

## Conditions studied

- HER2 + Breast Cancer

## Interventions

- **DRUG:** HLX87+HX22
- **DRUG:** HLX87 + Pertuzumab
- **DRUG:** TCbHP

## Key facts

- **NCT ID:** NCT07294534
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-27
- **Primary completion:** 2028-09-30
- **Final completion:** 2030-02-01
- **Target enrollment:** 817 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07294534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07294534, "A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07294534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*